Clinical Trial Update: Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan

View source ↗

Summary

A post-marketing surveillance study of Ofev (nintedanib) in Japanese patients with chronic fibrosing interstitial lung diseases with a progressive phenotype has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrosing Interstitial Lung Disease
• Interstitial Lung Disease

Drugs mentioned

• OFEV (Nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Lung Diseases, Interstitial | Status: COMPLETED | Results posted: 2026-02-06